Elucidating the cardioprotective mechanisms of sodium-glucose cotransporter-2 inhibitors beyond glycemic control

Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as a pivotal intervention in diabetes management, offering significant cardiovascular benefits. Empagliflozin, in particular, has demonstrated cardioprotective effects beyond its glucose-lowering action, reducing heart failure hospitaliz...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of diabetes Vol. 15; no. 2; pp. 137 - 141
Main Authors Zhang, Ke-Xin, Kan, Cheng-Xia, Han, Fang, Zhang, Jing-Wen, Sun, Xiao-Dong
Format Journal Article
LanguageEnglish
Published United States 15.02.2024
Subjects
Empagliflozin
Diabetes
Cardiovascular diseases
Sodium-glucose cotransporter-2
Online AccessGet full text

Cover

More Information
Summary:Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as a pivotal intervention in diabetes management, offering significant cardiovascular benefits. Empagliflozin, in particular, has demonstrated cardioprotective effects beyond its glucose-lowering action, reducing heart failure hospitalizations and improving cardiac function. Of note, the cardioprotective mechanisms appear to be inde-pendent of glucose lowering, possibly mediated through several mechanisms involving shifts in cardiac metabolism and anti-fibrotic, anti-inflammatory, and anti-oxidative pathways. This editorial summarizes the multifaceted cardiovascular advantages of SGLT2 inhibitors, highlighting the need for further research to elucidate their full therapeutic potential in cardiac care.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Editorial-2
ObjectType-Commentary-1
ISSN:1948-9358
1948-9358
DOI:10.4239/wjd.v15.i2.137